ICStudy, LLC Report issue

For profit Phase 3
Founded: Escondido CA United States (2009)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2011
NCT01295814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

IC Study, LLC

Active Ingredients

Drugs in Phase 3 Trials (2)

adalimumab (humira) (1 trial)

certolizumab pegol (cimzia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystitis (Phase 3)

Cystitis, Interstitial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2